Ovulation induction in women with polycystic ovary syndrome

摘要

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, anovulation and cystic ovarian morphology: Anovulation in women with PCOS results, in part, from low follicle-stimulating hormone (FSH) concentrations. Anovulatory infertility is the major complaint at presentation of many patients with PCOS, and several medications are available to induce ovulation. Some of these agents are approved for this indication in the US (e.g. clomifene citrate [CC]); others are unapproved but are, nonetheless, commonly used (e.g. metformin). The pros and cons of the available treatment options for anovulation in PCOS are discussed in this Viewpoint.